Seeing Is Believing
Currently out of the existing stock ratings of Peter Welford, 29 are a BUY (53.7%), 18 are a HOLD (33.33%), 7 are a SELL (12.96%).
Analyst Peter Welford, currently employed at JEFFERIES, carries an average stock price target met ratio of 48.89% that have a potential upside of 27.51% achieved within 373 days.
Peter Welford’s has documented 91 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 12-Nov-2024.
Analyst best performing recommendations are on CGEN (COMPUGEN).
The best stock recommendation documented was for PLX (PROTALIX BIOTHERAPEUTICS) at 9/6/2016. The price target of $8 was fulfilled within 156 days with a profit of $1.8 (29.03%) receiving and performance score of 1.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$87
$18.54 (27.08%)
$78
4 months 18 days ago
(18-Nov-2024)
8/9 (88.89%)
$23.61 (37.25%)
588
Buy
$88
$19.54 (28.54%)
$82
4 months 23 days ago
(13-Nov-2024)
4/5 (80%)
$22.71 (34.78%)
297
Buy
$95
$26.54 (38.77%)
$66
7 months 24 days ago
(12-Aug-2024)
6/7 (85.71%)
$12.48 (15.12%)
382
Buy
$85
$16.54 (24.16%)
$80
10 months 6 days ago
(30-May-2024)
4/4 (100%)
$8.7 (11.40%)
391
Buy
$84
$15.54 (22.70%)
$85
11 months 14 days ago
(22-Apr-2024)
2/12 (16.67%)
$14.3 (20.52%)
163
Which stock is Peter Welford is most bullish on?
What Year was the first public recommendation made by Peter Welford?